Serina Therapeutics, Inc. (SER) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing drug product candidates for neurological diseases using its proprietary POZ drug delivery technology. The reporting period covers the three months ended March 31, 2026. The Company is headquartered in Huntsville, Alabama, and operates as a single segment focused on research and development.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6.90) million | $(4.82) million |
| Net Loss Per Share (Basic & Diluted) | $(0.58) | $(0.49) |
| Operating Expenses | $6.28 million | $5.86 million |
| Cash and Cash Equivalents (End of Period) | $24.53 million | $4.27 million |
| Net Cash Used in Operating Activities | $(4.57) million | $(4.32) million |
| Net Cash Provided by Financing Activities | $26.06 million | $4.92 million |
| Total Debt (Convertible Note, net) | $3.01 million | N/A |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $2.08 million (43%) compared to Q1 2025, driven primarily by a $1.62 million non-cash loss on the extinguishment of financial commitment assets and contingent warrants.
- Operating Expenses: Total operating expenses rose by $0.42 million. Research and Development (R&D) expenses increased by $0.25 million due to higher headcount and clinical activity, while General and Administrative (G&A) expenses increased by $0.17 million.
- Liquidity Position: Cash balances increased significantly from $3.06 million at the start of the period to $24.53 million, fueled by $26.06 million in financing proceeds.
- Other Income/Expense: Shifted from a net gain of $1.04 million in Q1 2025 to a net expense of $0.61 million in Q1 2026, largely due to the extinguishment loss offsetting gains from changes in fair value of warrant and tranche liabilities.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for the twelve months following the issuance of these financial statements. Current cash ($24.5 million) plus subsequent proceeds ($5.2 million received in April 2026) are deemed insufficient to meet anticipated operating requirements.
- Financing Activity: The Company completed a "March 2026 PIPE" (Private Investment in Public Equity) raising approximately $21.2 million in gross proceeds (including $5.2 million in April 2026). This involved the issuance of common stock, pre-funded warrants, and redeemable warrants.
- Clinical Progress: The FDA cleared the IND application for the lead candidate, SER-252 (POZ-apomorphine), in January 2026 after a temporary clinical hold. The Company dosed its first patient in a Phase 1b study in February 2026.
- Risk Factors: Key risks include the need for additional capital, potential dilution from the PIPE transaction (where a Board member may own ~38% of shares), and the uncertainty of clinical trial outcomes and regulatory approvals.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion given the "substantial doubt" disclosure and the reliance on future financing.
- Pipe Terms: Review the terms of the March 2026 PIPE, specifically the exercise prices of pre-funded warrants ($0.0001) and redeemable warrants ($5.00), and the conditions for the automatic conversion of Series A Preferred Stock.
- Non-Cash Charges: Confirm the impact of the $1.62 million loss on extinguishment of financial commitments on the reported net loss versus actual cash burn.
- Series A Conversion: Note that the Series A Preferred Stock automatically converted to common stock in April 2026 at an adjusted price of $2.25 per share.
- Related Party Transactions: Assess the implications of the Board member (Dr. Gregory H. Bailey) acting as the lead investor in the PIPE and becoming Co-Chairman of the Board.